Comparing diagnostic prostate cancer biomarkers using a framework of clinically meaningful criteria
Open Access
- 22 September 2026
- journal article
- research article
- Published by Wiley in BJUI Compass
- Vol. 7 (9) , e70275
Abstract
Objectives: To synthesize existing biomarker literature and generate a framework for meaningful comparison between five commonly used diagnostic prostate cancer biomarkers—prostate health index ( phi ), 4KScore, SelectMDx, ExoDx and MyProstate Score (MPS)—to provide evidence of greatest practical value to providers managing men with an elevated prostate‐specific antigen (PSA) who are considering prostate biopsy. Materials and methods: Ten biomarker characteristics reflecting validity , usability and utility were designated as most clinically salient in guiding diagnostic prostate cancer biomarker selection. Whereas usability reflects how well a biomarker individualizes risk and optimizes patient concerns, utility reflects a biomarker's clinical usefulness. A systematic review of the biomarker literature from 2010 to 2022 was performed, and the criteria for each biomarker characteristic were first inductively defined and subsequently determined for each respective biomarker. Results: Nearly all biomarkers possess wide validity , with phi , 4KScore and MPS validated in Black populations. Compared to other biomarkers, 4KScore had the best usability . For urine‐based biomarkers, the better usability of ExoDx versus MPS is offset by its worse validity and utility . All serum‐based biomarkers have very high discriminative accuracy and were consequently more accurate in detecting high‐grade prostate cancer versus urine‐based biomarkers. Overall, 4KScore had the best utility . Conclusion: Our framework enables meaningful comparison of diagnostic prostate cancer biomarkers using criteria most salient to patients and clinicians. We demonstrate that the 4KScore currently possesses the best overall features; despite emerging evidence, more clinical utility, comparative and non‐White population validation studies are needed.Keywords
This publication has 27 references indexed in Scilit:
- Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk CalculatorEuropean Urology Focus, 2019
- Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic ReviewEuropean Urology Focus, 2018
- A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2–10 ng/ml at Initial BiopsyEuropean Urology, 2018
- A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American MenJournal of Urology, 2018
- Biomarkers in prostate cancer – Current clinical utility and future perspectivesCritical Reviews in Oncology/Hematology, 2017
- Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate CancerJAMA Oncology, 2017
- A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial BiopsyJAMA Oncology, 2016
- Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk AssessmentEuropean Urology, 2016
- The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic ReviewEuropean Urology, 2008
- Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or LowerJAMA, 2005